Subscribe
eye-istock-489756064-mark_kuiken-
Mark_Kuiken / iStockphoto.com
26 September 2017Americas

Native American tribe aims to dismiss Allergan patent IPRs

The Saint Regis Mohawk Tribe has attempted to dismiss inter partes reviews (IPR) brought by Mylan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.

More on this story

Americas
Tech companies have their say on Allergan-tribe deal at PTAB
4 December 2017   The Computer & Communications Industry Association (CCIA) and the Association for Accessible Medicines (AAM) have urged the Patent Trial and Appeal Board (PTAB) to dismiss a Native American tribe’s attempt to shut down a series of inter partes reviews (IPRs).
Americas
Native American tribe not entitled to sovereign immunity: PTAB
26 February 2018   The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.
Americas
The future of sovereign immunity deals after Allergan ruling
1 March 2018   Late last week, the Patent Trial and Appeal Board rejected a Native American tribe’s attempt to dismiss inter partes reviews based on the tribe’s sovereign immunity claims.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent